Skip to main content
SpringerLink
Log in

Hypertension and atrial fibrillation

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Atrial fibrillation (AF) is an emerging public health problem. The most important risk factor for developing chronic AF is uncontrolled hypertension. Uncontrolled hypertension promotes the initiation and perpetuation of AF through atrial remodeling. Experimental evidence has demonstrated the important role of the renin-angiotensin system in atrial remodeling. Retrospective analysis of several large clinical trials and small prospective trials suggests the beneficial role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in preventing the onset and recurrence of AF in different populations. Several large prospective trials with longer follow-up periods are in progress. These trials may provide definitive evidence for the use of these agents in the prevention of AF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. American Heart Association: Heart Disease and Stroke Statistics: 2005 Update. Dallas, TX: American Heart Association; 2005.

    Google Scholar 

  2. Lloyd-Jones DM, Wang TJ, Leip EP, et al.: Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004, 110:1042–1046.

    Article  PubMed  Google Scholar 

  3. Benjamin EJ, Levy D, Vaziri SM, et al.: Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA 1994, 271:840–844.

    Article  CAS  PubMed  Google Scholar 

  4. Miyasaka Y, Barnes ME, Gersh BJ, et al.: Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006, 114:119–125.

    Article  PubMed  Google Scholar 

  5. Whelton PK: Epidemiology of hypertension. Lancet 1994, 344:101–106.

    Article  CAS  PubMed  Google Scholar 

  6. Nieuwlaat R, Capucci A, Camm AJ, et al.: Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005, 26:2422–2434.

    Article  PubMed  Google Scholar 

  7. Tan AY, Zhou S, Ogawa M, et al.: Neural mechanisms of paroxysmal atrial fibrillation and paroxysmal atrial tachycardia in ambulatory canines. Circulation 2008, 118:916–925.

    Article  PubMed  Google Scholar 

  8. Hoffman E, Sulke N, Edvardsson N, et al.: New insights into the initiation of atrial fibrillation. A detailed intraindividual and interindividual analysis of the spontaneous onset of atrial fibrillation using new diagnostic pacemaker features. Circulation 2006, 113:1933–1941.

    Article  Google Scholar 

  9. Tsang TS, Gersh BJ, Appleton CP, et al.: Left ventricular diastolic dysfunction as a predictor of the first diagnosed non-valvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 2002, 40:1636–1644.

    Article  PubMed  Google Scholar 

  10. Deroubaix E, Folliguet T, Rucker-Martin C, et al.: Moderate and chronic hemodynamic overload of sheep atria induces reversible cellular electrophysiologic abnormalities and atrial vulnerability. J Am Coll Cardiol 2004, 44:1918–1926.

    Article  PubMed  Google Scholar 

  11. Byrd GD, Prasad SM, Ripplinger CM, et al.: Importance of geometry and refractory period in sustaining atrial fibrillation. Testing the Critical Mass Hypothesis. Circulation 2005, 112(Suppl 1):I7–I13.

    PubMed  Google Scholar 

  12. Burstein B, Nattel S: Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008, 51:802–809.

    Article  CAS  PubMed  Google Scholar 

  13. Wijffels MC, Kirchhof CJ, Dorland R, et al.: Atrial fibrillation begets atrial fibrillation: a study in awake, chronically instrumented goats. Circulation 1995, 92:1954–1968.

    CAS  PubMed  Google Scholar 

  14. Tsai C, Hwang J, Shih Y, et al.: Evolution of left atrial systolic and diastolic functions in different stages of hypertension: distinct effects of blood pressure control. Cardiology 2008, 109:180–187.

    Article  PubMed  Google Scholar 

  15. Maruyama T, Kishikawa T, Ito H, et al.: Augmentation of pulmonary vein backflow velocity during left atrial contraction: a novel phenomenon responsible for progression of atrial fibrillation in hypertensive patients. Cardiology 2008, 109:33–40.

    Article  CAS  PubMed  Google Scholar 

  16. Goette A, Staack T, Rocken C, et al.: Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000, 35:1669–1677.

    Article  CAS  PubMed  Google Scholar 

  17. McEwan PE, Gray GA, Sherry L, et al.: Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 1998, 98:2765–2773.

    CAS  PubMed  Google Scholar 

  18. Stockand JD, Meszaros JG: Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-Ras and MAPK1/2 signaling. Am J Physiol Heart Circ Physiol 2003, 284:H176–H184.

    CAS  PubMed  Google Scholar 

  19. Mukherjee R, Herron AR, Lowry AS, et al.: Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol 2006, 15:532–537.

    Article  Google Scholar 

  20. Ehrlich JR, Hohnloser SH, Nattel S: Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 2006, 27:512–518.

    Article  CAS  PubMed  Google Scholar 

  21. Nakashima H, Kumagai K, Urata H, et al.: Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000, 101:2612–2617.

    CAS  PubMed  Google Scholar 

  22. Kumagai K, Nakashima H, Urata H, et al.: Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003, 41:2197–2204.

    Article  CAS  PubMed  Google Scholar 

  23. Cha Y, Dzeja PP, Redfield MM, et al.: Bioenergetic protection of failing atrial and ventricular myocardium by vasopeptidase inhibitor omapatrilat. Am J Physiol Heart Circ Physiol 2006, 290:H1686–H1692.

    Article  CAS  PubMed  Google Scholar 

  24. Li Y, Li W, Gong Y, et al.: The effects of cilazapril and valsartan on the mRNA and protein expressions of atrial calpains and atrial structural remodeling in atrial fibrillation dogs. Basic Res Cardiol 2007, 102:245–256.

    Article  CAS  PubMed  Google Scholar 

  25. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C: Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999, 100:376–380.

    CAS  PubMed  Google Scholar 

  26. Vermes E, Tardiff JC, Bourassa MG, et al.: Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: Insight from the Studies of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003, 107:2926–2931.

    Article  PubMed  Google Scholar 

  27. Alsheikh-Ali AA, Wang PJ, Rand W, et al.: Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction. Am Heart J 2004, 147:1061–1065.

    Article  CAS  PubMed  Google Scholar 

  28. Maggioni AP, Latini R, Carson PE, et al.: Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005, 149:548–557.

    Article  CAS  PubMed  Google Scholar 

  29. McMurray JJ, Young JB, Dunlap ME, et al.: Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM)-added trial. Am Heart J 2006, 151:985–991.

    Article  CAS  Google Scholar 

  30. Schmeider R, Kjeldsen SE, Julius S, et al.: Reduced incidence of new onset atrial fibrillation with angiotensin II receptor blockade: the VALUE-trial [abstract]. J Hypertens 2006, 24(Suppl 6):31.

    Article  Google Scholar 

  31. Wachtell K, Lehto M, Gerdts E, et al.: Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared with atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005, 45:712–719.

    Article  CAS  PubMed  Google Scholar 

  32. Wachtell K, Hornestam B, Lehto M, et al.: Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005, 1:705–711.

    Article  Google Scholar 

  33. Okin PM, Wachtell K, Devereux RB, et al.: Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 2006, 296:1242–1248.

    Article  CAS  PubMed  Google Scholar 

  34. L’Allier PL, Ducharme A, Keller PF, et al.: Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 2004, 44:159–164.

    Article  PubMed  Google Scholar 

  35. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension. The Captopril Prevention Project (CAPP) Randomized Trial. Lancet 1999, 353:611–616.

    Article  CAS  PubMed  Google Scholar 

  36. Hansson L, Lindholm LH, Ekbom T, et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular morbidity and mortality in the Swedish Trial in Old Patients with Hypertension-2 Study. Lancet 1999, 354:1751–1756.

    Article  CAS  PubMed  Google Scholar 

  37. Pizetti F, Turazza FM, Franzosi MG, et al.: Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction. The GISSI-3 data. Heart 2001, 86:527–532.

    Article  Google Scholar 

  38. Murray KT, Rottman JN, Arbogast PG, et al.: Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm 2004, 1:669–675.

    Article  PubMed  Google Scholar 

  39. Salehian O, Healey J, Stambler B, et al.: Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study (HOPE). Am Heart J 2007, 154:448–453.

    Article  CAS  PubMed  Google Scholar 

  40. Zaman AG, Kearney MT, Schecter C, et al.: Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation. Am Heart J 2004, 147:823–827.

    Article  CAS  PubMed  Google Scholar 

  41. Madrid AH, Bueno MG, Rebullo JM, et al.: Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002, 106:331–336.

    Article  CAS  PubMed  Google Scholar 

  42. Ueng KC, Tsai TP, Yu WC, et al.: Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003, 34:2090–2098.

    Article  Google Scholar 

  43. Dagres N, Karatasakis G, Panou F, et al.: Pre-treatment with irbesartan attenuates left atrial stunning after electrical cardioversion. Eur Heart J 2006, 27:2062–2068.

    Article  CAS  PubMed  Google Scholar 

  44. Tveit A, Grundvold I, Olufsen M, et al.: Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol 2007, 120:85–91.

    Article  PubMed  Google Scholar 

  45. Fogari R, Mugellini A, Destro M, et al.: Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol 2006, 47:46–50.

    Article  CAS  PubMed  Google Scholar 

  46. Yusuf S, Teo KK, Pogue J, Dyal L, et al.: Telmisartan, ramipril or both in patients at high risk for vascular events. New Engl J Med 2008, 358:1547–1559.

    Article  CAS  PubMed  Google Scholar 

  47. The GISSI-AF Investigators: Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009, 360:1606–1617.

    Article  Google Scholar 

  48. ClinicalTrials.gov: Trial to Investigate the Efficacy of Olmesartan in Paroxysmal Atrial Fibrillation. Available at http://clinicaltrials.gov/show/NCT00098137. Accessed August 2009.

  49. Yamashita T, Ogawa S, Aizawa Y, et al.: Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension. The J-RHYTHM II Study design for the investigation of upstream therapy for atrial fibrillation. Circ J 2006, 70:1318–1321.

    Article  PubMed  Google Scholar 

  50. Tardif JC, Talajic M: Perindopril and prevention of atrial fibrillation. Eur Heart J Suppl 2007, 9:E25–E29.

    Article  CAS  Google Scholar 

  51. ClinicalTrials.gov: Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE I). Available at http://clinicaltrials.gov/show/NCT00249795. Accessed August 2009.

  52. Fuster V, Rydén LE, Cannom DS, et al.: ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. Circulation 2006, 114:700–752.

    Article  Google Scholar 

  53. Hohnloser SH, Crijns HJ, van Eickels M, et al.: Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009, 360:668–678.

    Article  CAS  PubMed  Google Scholar 

  54. Rosendorff C, Black HR, Cannon CP, et al.: Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007, 115:2761–2788.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mount Sinai School of Medicine, Medicine (111), James J. Peters VA Medical Center, 130 West Kingsbridge Road, Bronx, NY, 10468, USA

    Clive Rosendorff

Authors
  1. Orson Go
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Clive Rosendorff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Clive Rosendorff.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Go, O., Rosendorff, C. Hypertension and atrial fibrillation. Curr Cardiol Rep 11, 430–435 (2009). https://doi.org/10.1007/s11886-009-0062-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-009-0062-4

Keywords

Search

Navigation